Servier Canada company information, Employees & Contact Information

Bio-S: a unique facility in Europe for the clinical manufacture of new biodrugs Servier

Servier acquires potential treatment for Fragile X syndrome, the most common genetic cause of autism spectrum disorder PR Newswire Canada

VORANIGO approved by Health Canada for IDH-mutant glioma Pharmaceutical Technology

Servier gets Health Canada nod for Voranigo to treat brain cancer World Pharmaceutical Frontiers

Jacques Servier, 92, Dies; Accused of Hiding the Risks of Drugs (Published 2014) The New York Times

Learn more about our development portfolio Servier

See our bases throughout the world Servier

The Group in figures Servier

Our ambition for 2030 Servier

Servier and Black Diamond Therapeutics Announce Global Licensing Agreement for BDTX-4933, A Targeted Oncology Therapy Servier

Palm Therapeutics wins Servier Discovery Award for its work in the life sciences Servier

Servier x Owkin: AI-driven precision therapeutics Servier

Servier backs a Californian startup research project to accelerate therapeutic innovation Servier

7 start-ups hosted Servier

Our commitment to oncology Servier

Nicolas Garnier joins Servier as Chief Patient Officer Servier

Servier is boosting its digital transformation with Google Cloud! Servier

All our latest news Servier

The Research and Development Institute in Paris-Saclay Servier

Servier completes acquisition of Agios Pharmaceuticals’ oncology business Servier

Servier's beefing up in oncology through dealmaking and Tibsovo wins—and it's not done yet, U.S. CEO says Fierce Pharma

Servier's Vorasidenib Receives Approval as Clinical Urgently Needed Drug to be Used in Boao Lecheng Pilot Zone PR Newswire

Canada to Ban Non-Compete Clauses in Federally Regulated Workplaces PYMNTS.com

The Servier Group opens a worldwide Artificial Intelligence Hub in Montreal, in partnership with Centech GlobeNewswire

Sorrento nabs PD-1 deal with Servier Fierce Biotech

Servier Canada to market edoxaban in Canada European Pharmaceutical Review

Health Canada Approves First and Only Oral Targeted Treatment for Brain Cancer Oncodaily

Servier, VCs invest $21 mln to create new Québec biotech startup Venture Capital Journal

Servier unveils its 2030 ambition and reveals a new visual identity PR Newswire Canada

Health Canada Approves First and Only Oral Targeted Treatment for Brain Cancer PR Newswire Canada

Servier Canada, in collaboration with Hypertension Canada, launches the GETDOWNBP Hypertension Management mobile App PR Newswire Canada

Robotics, AI key to faster cardiac ultrasound system under development | Folio University of Alberta

Servier UK appoints new chief executive Pharmafile

ENVISAGE-TAVI AF Study Investigating Once-Daily LIXIANA® (edoxaban) in Patients with Atrial Fibrillation Undergoing Transcatheter Aortic Valve Implantation was initiated PR Newswire Canada

It takes a village: community of experts pulls together for young heart transplant recipient University of Alberta

LIXIANA® (edoxaban) now reimbursed by the Régie de l'assurance maladie du Québec for patients with atrial fibrillation or venous thromboembolism PR Newswire Canada

2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary CMAJ

To stay or not to stay: the Quebec Court of Appeal provides clarification on the test to be applied McCarthy Tétrault LLP

Once-Daily Anticoagulant LIXIANA® (edoxaban) Approved in Canada for Stroke Prevention in Atrial Fibrillation and for the Treatment and Prevention of Recurrent Deep-Vein Thrombosis and Pulmonary Embolism PR Newswire Canada

Viacoram® now approved in Canada as a new first line treatment in hypertension PR Newswire Canada

LANCORA™ (ivabradine) now covered by the Ontario Public Drug Program and British Columbia PharmaCare for patients suffering from chronic heart failure PR Newswire Canada